Kodiak Sciences Inc.: directors' dealings · United States · SEC (Form 4)

About Kodiak Sciences Inc.

Kodiak Sciences Inc. is a United States biopharmaceutical company listed on the NASDAQ market (United States) and focused on retinal and ophthalmic diseases with high unmet medical need. The company was founded in 2009 as Oligasis LLC and later adopted the Kodiak Sciences name. Its principal executive office is in Palo Alto, California. For investors, Kodiak should be viewed as a clinical-stage biotech: it is still in the development phase, with no large-scale commercial franchise yet, and its value proposition depends primarily on clinical execution, regulatory progress and the future marketability of its pipeline. Kodiak’s core scientific engine is its proprietary ABC Platform (Antibody Biopolymer Conjugate), which is designed to combine biologics and chemistry to deliver retinal medicines with greater durability and potentially improved dosing convenience. The company’s lead programs include tarcocimab tedromer, now also referenced under the brand name Zenkuda, as well as KSI-501 and KSI-101. These programs target a range of retinal conditions including diabetic retinopathy, retinal vein occlusion, wet age-related macular degeneration, and macular edema secondary to inflammation. From a competitive standpoint, Kodiak operates in a highly specialized and crowded field where large pharmaceutical companies and ophthalmology-focused biotechs compete around anti-VEGF therapies, inflammation pathways, and longer-acting intravitreal treatment options. Kodiak’s differentiation thesis is centered on durability, efficacy and a flexible dosing profile that could, if validated, improve adherence and expand physician adoption. In other words, the company is positioning itself around a next-generation retina franchise rather than a commodity follow-on therapy. Recent company developments have been important for the investment case. In 2025 and 2026, Kodiak raised capital through equity offerings, underscoring the capital-intensive nature of late-stage biotech development. More importantly, the company reported positive Phase 3 topline results for GLOW2 in diabetic retinopathy, announced additional clinical and scientific updates for KSI-101, and advanced the DAYBREAK program. These milestones improve pipeline visibility and suggest continued momentum toward a potential registration package, although the company remains exposed to the usual biotech risks: clinical trial uncertainty, regulatory review risk, funding needs and eventual commercialization execution. Overall, Kodiak Sciences represents a focused U.S. retinal biotech with meaningful optionality, but also with binary clinical and regulatory dependencies typical of late-stage development companies.